Ionis Pharmaceuticals Inc (IONS) Receives a Hold from Cowen & Co.

Cowen & Co. analyst Ritu Baral maintained a Hold rating on Ionis Pharmaceuticals Inc (IONSResearch Report) yesterday. The company’s shares closed yesterday at $67.68.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 22.3% and a 48.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Currently, the analyst consensus on Ionis Pharmaceuticals Inc is a Hold with an average price target of $68.29, a 0.9% upside from current levels. In a report issued on July 23, J.P. Morgan also reiterated a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Based on Ionis Pharmaceuticals Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $87.54 million. In comparison, last year the company had a GAAP net loss of $40.36 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.